Evolution of CAR technology: from conventional CAR-T cells to diverse cellular platforms and clinical applications. (IMAGE)
Caption
Evolution of CAR technology: from conventional CAR-T cells to diverse cellular platforms and clinical applications. An overview of different CAR cell platforms, outlining their main advantages over conventional CAR-T cells. The flow begins with the major challenges hindering conventional CAR-T cell therapies, such as systemic toxicities, manufacturing hurdles, and resistance in solid tumors. To address these limitations, the field is expanding toward diverse cellular platforms, including various immune effectors and non-immune cells, each offering unique mechanistic advantages. Finally, this diversification facilitates the expansion of therapeutic indications, moving beyond hematologic malignancies to encompass solid tumors, autoimmune diseases, chronic infections, and other diseases.
Credit
Precision Clinical Medicine
Usage Restrictions
Credit must be given to the creator.
License
CC BY